Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTJonathan Ponciano, The Motley FoolSat, June 27, 2026 at 6:23 PM GMT+2 4 min readOn June 22, 2026, Orbimed Advisors, a 10% Owner of Enliven Therapeutics, Inc. (NASDAQ:ELVN), disclosed the indirect sale of 860,123 shares for a total transaction value of approximately $39.0 million, as reported in the SEC Form 4 filing.Transaction summaryMetricValueShares sold (indirect)860,123Transaction value~$39.0 millionPost-transaction shares (indirect)6,555,102Transaction value based on SEC Form 4 weighted average purchase price ($45.36); post-transaction value based on June 22, 2026 market close.Key questionsWhat is the structure of Orbimed's ownership post-transaction?Following this transaction, all remaining 6,555,102 shares reported in the filing are held indirectly through OrbiMed Genesis Master Fund, L.P. and OrbiMed Private Investments VII, LP.What proportion of total holdings was impacted by this transaction?The sale represented 11.60% of Advisors Llc Orbimed's total indirect holdings prior to the transaction, reflecting a meaningful reduction in its aggregate ownership but not a full exit.How does current trading context relate to the transaction price?The shares were sold at around $45.36 per share, while the stock closed at $45.96 on June 22, 2026, and subsequently increased to $50 as of June 26, 2026, indicating a modest appreciation post-sale.Company overviewMetricValueMarket capitalization$3.6 billionNet income (TTM)-$98.78 million1-year price change130%* 1-year performance calculated using June 22nd, 2026 as the reference date.Company snapshotEnliven Therapeutics focuses on the clinical development of small-molecule kinase inhibitors, with its leading candidates ELVN-001 (for chronic myeloid leukemia) and ELVN-002 (for HER2-mutant cancers) both in Phase 1 trials.The company operates a research-driven model, aiming to generate future revenue by successfully developing, obtaining regulatory approval, and commercializing or licensing its oncology drug candidates.The primary target market includes adult patients with cancer, specifically those with chronic myeloid leukemia or HER2-driven malignancies, as well as the healthcare providers and institutions treating these populations.Enliven Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Boulder, Colorado, with a focus on innovative small-molecule therapies for cancer. With a lean team, the company channels resources into advancing its pipeline of kinase inhibitors for high-need oncology indications. Its strategy centers on leveraging deep scientific expertise to address unmet medical needs and create differentiated therapies in the competitive cancer therapeutics landscape.Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info